Prediction of lymph node status in completely resected IIla/N2 small cell lung cancer: importance of subcarinal station metastases

Rong Qiao†, Runbo Zhong†, Jianlin Xu, Yanwei Zhang, Bo Zhang, Shuyuan Wang, Yuqing Lou, Dongfang Chen, Qing Chang, Yizhuo Zhao and Baohui Han*

Abstract

Background: The aim of this study was to determine the prognostic value of lymph node status in patients with pathologic N2 (pN2) stage IIIA small cell lung cancer (SCLC).

Methods: A total of 163 consecutive pN2 stage IIIA SCLC patients who underwent pulmonary resections and systematic lymphadenectomies at Shanghai Chest Hospital between January 2006 and June 2014 were enrolled. We retrospectively analyzed the potential clinicopathologic factors that influenced survival, including the node levels (single or multiple-station) and the node-spreading patterns (skip N2 or non-skip N2). The prognostic significance was examined by Cox regression analysis.

Results: The median overall survival (OS) was 23.7 months. Multiple-station lymph node metastasis indicated a poorer prognosis than single-station involvement (p = 0.003). Skip metastasis did not appear to influence survival (p = 0.099). With respect to the station of lymph node metastasis, the OS was only related to the involvement of the subcarinal node, regardless of tumor location (p < 0.05). Multivariate analysis showed two statistically significant risk factors for survival, including multiple-station lymph node and subcarinal node metastasis (hazard ratio [HR] = 1.76, 95% confidence interval [CI]: 1.11–2.78, p = 0.015; HR = 1.61, 95% CI: 1.03–2.50, p = 0.036, respectively).

Conclusions: Multiple-station N2 metastasis and involvement of the subcarinal node predicted poor prognosis in pN2 stage IIIA SCLC patients, which may profoundly influence therapeutic decisions.

Keywords: Small cell lung cancer, N2 disease, Subcarinal lymph node, Prognostic factors

Introduction

Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related deaths worldwide [1]. Small cell lung cancer (SCLC) accounts for ~15% of all newly diagnosed lung cancer cases [2]. SCLC is more aggressive than non-small cell lung cancer (NSCLC) because of the more rapid doubling time, higher growth fraction, and earlier metastatic spread [3]. Chemoradiation therapy is recommended as standard management in patients with limited-stage SCLC. However, several large population database series have recently reported favorable survival outcomes in limited-stage patients who underwent surgery combined with non-surgical treatment, even for stage IIIA disease [4, 5]. Thus, the diagnosis of SCLC is sometimes difficult from small specimens obtained by bronchoscopy and/or needle biopsy. Most patients did not have a confirmed diagnosis of SCLC pre- or intra-operatively, until a surgically-resected specimen showed SCLC, even though there was no suspicion of N2 lymph node (LN)
metastasis. Indeed, surgical resection is increasingly used for pN2 IIIA SCLC; however, the prognostic impact of LN involvement in surgically-treated SCLC has been rarely evaluated to date. Therefore, to achieve better local control, ascertaining prognostic factors has been especially important to guide post-operative multidisciplinary treatment and helpful to identify appropriate sub-groups of N2 patients who can benefit from surgical intervention.

In this study we investigated the node levels and spreading patterns in patients with completely resected SCLC with pathologic N2 (pN2) stage IIIA, and to identify the subgroups which may affect post-operative survival.

Materials and methods
Patients
We retrospectively reviewed the patients with pN2 stage IIIA SCLC who underwent surgical resection at Shanghai Chest Hospital between January 2006 and June 2014. Patients with post-operative follow-up for at least 3 months, Eastern Cooperative Oncology Group performance status 0–1, a single primary tumor, systematic mediastinal nodal dissection, negative resection margins, and no pre-operative neoadjuvant therapy (chemotherapy and/or radiation therapy) were included. The current study was conducted with approval of the Institutional Review Board of Shanghai Chest Hospital.

We recorded the following clinicopathologic variables in the analysis: age; gender; smoking history; positron emission tomography (PET) scan; tumor endoscopy (central and peripheral); tumor location (upper, middle, and lower lobes); pre-operative diagnosis; type of resection; histologic type; visceral pleura invasion; lymphovascular invasion (LVI); pathologic tumor size (cm); post-surgical N stage; number and pattern of LN involvement; and administration of induction and/or adjuvant treatments.

Classification and definition of pathologic N status
Surgical-pathologic staging was assigned according to the 7th edition of the tumor–node–metastasis classification system. N2 LNs were classified according to the LN map published by the 2009 International Association for the Study of Lung Cancer [6]. Metastasis to the pN2 was classified as follows:

1. according to the node levels (single-station [metastasis to one N2 station] or multiple-station [metastases to 2 or more N2 stations] N2 metastases); and
2. according to the node-spreading patterns (skip [N2 lymph node metastases without any N1 node involvement] or non-skip [N2 lymph node metastases with N1 node involvement] N2 metastases).

Statistical analysis
Overall survival (OS) was defined as the time from surgery to death from any cause or the last follow-up date. Statistical analysis was performed using a χ2 test for categorical variables and an unpaired t-test for continuous variables. Survival curves was estimated using the Kaplan–Meier method and compared by a log-rank test. Univariate analysis used the following outcome variables: patient age, sex, smoking status, PET (positron emission tomography) scan, histology, tumor endoscopy, visceral pleura invasion, lymphovascular invasion, tumor size, node levels, node-spreading patterns, subcarinal LN metastasis, cycles of chemotherapy, PORT to the lung and PCI. Multivariate survival analysis using the Cox proportional hazards regression model was performed to assess the prognostic significance of pN2 sub-classification, including clinicopathologic variables. Binary logistic regression was used to analyze independent risk factors correlated to subcarinal lymph node metastasis. A two-sided p-value < 0.05 was defined as statistically significant. Statistical analyses were performed using SPSS software (version 22; SPSS, Inc., Chicago, IL, USA).

Results
Patient characteristics
A total of 163 consecutive patients with pN2 stage IIIA SCLC were included in this retrospective analysis (Fig. 1). The demographic data of all patients are summarized in Table 1. Among the 163 patients, 132 (81.0%) were male and 31 (19.0%) were female. The mean age was 58.7 ± 8.7 years, with an age range from 33 to 79 years. All of the patients had a bronchoscopy examination with bronchial brushing. 63 (38.7%) patients receive PET-staged to assess the mediastinal lymph nodes. 102 (62.5%) patients underwent preoperative biopsy by CT-guided transthoracic needle aspiration and/or bronchoscopy. 40 (24.5%) patients were preoperatively diagnosed with SCLC, 37 (22.7%) patients were diagnosed with other types of cancer (included unclassified carcinoma), and 86 (52.8%) patients received CT-guided transthoracic needle aspiration and/or bronchoscopy (including EBUS) with negative results. The pathologic sub-type was pure SCLC in 117 patients (71.8%) and combined SCLC in the remaining 46 patients. The most frequent procedure was a lobectomy (81.6%). One hundred eleven patients (68.1%) received post-operative radiotherapy (PORT) to the lung. The median delivered dose was 52.8 Gy (range, 30–80 Gy). Fifty-five patients (33.7%) received prophylactic cranial irradiation (PCI). All patients received adjuvant chemotherapy within 28–45 days after surgery. Different chemotherapy regimens were used: 96 patients received cisplatin plus etoposide, 60 patients received etoposide plus carboplatin, and only 7 patients received etoposide alone. 67 patients (41.1%) received more than
four cycles of adjuvant chemotherapy. Single- and multiple-station N2 was present in 85 (52.1%) and 78 patients (47.9%), respectively. Skip metastases were recorded in 26 patients (16.0%).

pN2 subclassification and survival
The overall follow-up ranged from 13 to 140 months with a median of 50 months. The median OS was 23.7 months (hazard ratio [HR], 1.33, 95% confidence interval [CI], 21.1–26.3) among all patients. The levels and locations of involved nodes affecting survival (Fig. 2). Although skip N2 metastasis was not associated with OS ($p = 0.099$), the node levels were significantly related with OS ($p = 0.003$). The OS was 25.71 months (HR, 2.88, 95% CI, 20.07–31.35) and 17.31 months (HR, 3.72, 95% CI, 10.01–24.61) for patients with single- and multiple-station N2 metastasis, respectively. Furthermore, the OS for patients without subcarinal LN metastasis (29.36 months; HR, 4.73, 95% CI, 20.09–38.63) was significantly longer than patients with subcarinal LN metastasis (16.14 months; HR, 2.11, 95% CI, 12.01–20.27; $p < 0.05$). The remaining LNs, including metastases of stations 2,3,4,5,6,8, and 9, were of no statistical significance with respect to OS (data not shown).

Univariate Cox analyses showed that tumor endoscopy, tumor size, LVI, PORT to the lung, PCI, N2 levels, and subcarinal LN metastasis were predictive of survival (Table 2). Multivariate analyses confirmed that PORT to the lung (yes versus no; HR, 1.53, 95% CI, 1.01–2.32, $p = 0.041$), PCI (yes versus no; HR, 2.10; 95% CI, 1.31–3.36, $p = 0.002$), node levels (single versus multiple; HR, 1.84, 95% CI, 1.19–2.84, $p = 0.006$), and subcarinal LN metastasis (no versus yes; HR, 1.57, 95% CI, 1.02–2.41, $p = 0.037$) were independent prognostic factors (Table 3).

Subcarinal LN metastasis
Subcarinal LN metastasis was observed in 74 (45.4%) of the 163 patients with N2 disease. Among the 36 patients with N2 disease of the right upper lobe, 10 (27.8%) had subcarinal LN. Similarly, of the 48 patients with N2 disease in the left upper lobe, 8 (16.7%) had subcarinal LN involvement. Of the 52 patients with N2 disease of the right middle and lower lobes, 39 (75%) had subcarinal LN involvement. Among the 27 patients with N2 in the left lower lobe, 17 (63%) had subcarinal LN involvement. The most common locations for the primary tumor in cases with subcarinal LN metastases were in the left lower (63%) and right lower lobes (74%).

Among the variables potentially associated with subcarinal LN metastasis, tumor location, tumor size, and node levels differed significantly between patients with and without subcarinal LN metastasis (Table 1). As
| Variables                        | All patients | Subcarinal node (−) | Subcarinal node (+) | \( p \) value |
|---------------------------------|--------------|---------------------|---------------------|----------------|
| **Age at surgery**              |              |                     |                     |                |
| ˂ 60 years                      | 89 (54.6%)   | 49                  | 40                  | 0.898          |
| ˃≥ 60 years                     | 74 (45.4%)   | 40                  | 34                  |                |
| **Gender**                      |              |                     |                     |                |
| Male                            | 132 (81.0%)  | 74                  | 58                  | 0.440          |
| Female                          | 31 (19.0%)   | 15                  | 16                  |                |
| **Smoking status**              |              |                     |                     |                |
| Smoker                          | 121 (74.2%)  | 67                  | 54                  | 0.737          |
| Never-smoker                    | 42 (25.8%)   | 22                  | 20                  |                |
| **PET scan**                    |              |                     |                     |                |
| Yes                             | 63 (38.7%)   | 34                  | 29                  | 0.897          |
| No                              | 100 (61.3%)  | 55                  | 45                  |                |
| **Preoperative biopsy**         |              |                     |                     |                |
| SCLC                            | 40 (24.5%)   | 20                  | 20                  | 0.793          |
| Other types of cancer           | 37 (22.7%)   | 20                  | 17                  |                |
| Cancer not diagnosed            | 86 (52.8%)   | 49                  | 37                  |                |
| **Surgery type**                |              |                     |                     |                |
| Lobectomy                       | 133 (81.6%)  | 72                  | 61                  | 0.801          |
| Pneumonectomy                   | 30 (18.4%)   | 17                  | 13                  |                |
| **Histology**                   |              |                     |                     |                |
| Pure SCLC                       | 117 (71.8%)  | 67                  | 50                  | 0.276          |
| Combined SCLC                   | 46 (28.2%)   | 22                  | 24                  |                |
| **Tumor location**              |              |                     |                     |                |
| Upper lobe                      | 84 (51.5%)   | 66                  | 18                  | ˂ 0.05         |
| Middle lobe                     | 12 (7.4%)    | 2                   | 10                  |                |
| Lower lobe                      | 67 (41.1%)   | 21                  | 46                  |                |
| **Tumor endoscopy**             |              |                     |                     |                |
| Peripheral                      | 66 (40.5%)   | 37                  | 29                  | 0.758          |
| Central                         | 97 (59.5%)   | 52                  | 45                  |                |
| **Visceral pleura invasion**    |              |                     |                     |                |
| Yes                             | 23 (14.1%)   | 12                  | 11                  | 0.801          |
| No                              | 140 (85.9%)  | 77                  | 63                  |                |
| **LVI**                         |              |                     |                     |                |
| Yes                             | 44 (27.0%)   | 23                  | 21                  | 0.717          |
| No                              | 119 (73.0%)  | 66                  | 53                  |                |
| **Tumor size (cm)**             |              |                     |                     |                |
| ≤ 3                             | 3.69 ± 1.36  | 4.54 ± 1.81         | 0.001               |
| > 3, ≤ 5                        | 51 (31.3%)   | 34                  | 17                  | 0.005          |
| > 5                             | 77 (47.2%)   | 44                  | 33                  |                |
| **Cycles of Chemotherapy**      |              |                     |                     |                |
| ≤ 4                             | 96 (58.9%)   | 50                  | 46                  | 0.440          |
| > 4                             | 67 (41.1%)   | 39                  | 28                  |                |
| PCI                             |              |                     |                     |                |
indicated by the multivariate logistic regression analysis, the tumor size was not statistically significant independent risk factors predicting subcarinal LN involvement; however, tumor location (middle/lower versus upper; \( p < 0.05 \)) and node levels (multiple versus single; \( p < 0.05 \)) were associated with a 13.839-, 8.320-, and 4.041-fold increased risk of subcarinal LN metastasis, respectively (Table 4).

### Discussion

To date, the prognostic impact of the involved lymph nodes in surgically-resected SCLC has rarely been evaluated, and the identification of patients who might benefit from more aggressive post-operative therapy remains a challenge. Therefore, an assessment of the prognostic characteristics of LN metastasis in patients with SCLC is very useful in selecting appropriate patients for surgery and guide effective adjuvant therapy.

We reviewed 163 consecutive patients who underwent pulmonary resections for pN2 IIIA SCLC. Only 24.5% of patients were diagnosed SCLC before surgery. In our opinion, the accuracy of the pre-operative diagnosis is important to help establish the best treatment strategy, and may influence survival of patients with SCLC.

In this study, the percentage of multiple-station N2 was 24.5%, and survival analysis showed a greater number of N2 LNs was associated with worse OS (\( p = 0.003 \)). We also found that the worse prognostic value of multiple-station N2 involvement was highly significant (\( p = 0.015 \)). There have been several reports that have shown patients with involvement of multiple-station N2 have a worse prognosis than patients with single-station N2 involvement in completely resected pN2 NSCLC [7–11]. These reports were in agreement with our present study in patients with SCLC. Involvement of multiple-station N2 may imply increased tumor burden in the lymphatic flow and opportunity of systemic spread of tumor cells, which can lead to early recurrence of tumors [12].

Skip N2 metastasis is thought to be derived from subpleural lymphatics that drain directly to the mediastinum [7]. The incidence of skip N2 metastases is 20–40% of all N2 diseases in resected NSCLC [13], and our study (16.0%) was slightly lower than these previous reports. In resected pN2 NSCLC, several studies have suggested an increased survival for skip metastases [14–17];
### Table 2 Univariate analysis for overall survival

| Variables                  | Univariate Analysis |  \( p \) value |
|----------------------------|---------------------|---------------|
| **Age**                    |                     |               |
| < 60 years                 | 1                   | 0.703         |
| ≥ 60 years                 | 1.07 (0.73–1.57)    |               |
| **Gender**                 |                     |               |
| Male                       | 1                   | 0.790         |
| Female                     | 1.06 (0.65–1.74)    |               |
| **Smoking status**         |                     |               |
| Smoker                     | 1                   | 0.690         |
| Never-smoker               | 0.91 (0.59–1.40)    |               |
| **PET scan**               |                     |               |
| Yes                        | 1                   | 0.681         |
| No                         | 1.08 (0.73–1.59)    |               |
| **Histology**              |                     |               |
| Pure SCLC                  | 1                   | 0.486         |
| Combined SCLC              | 1.16 (0.75–1.79)    |               |
| **Tumor endoscopy**        |                     |               |
| Peripheral                 | 1                   | 0.005         |
| Central                    | 1.83 (1.20–2.78)    |               |
| **Visceral pleura invasion**|                    |               |
| Yes                        | 1                   | 0.624         |
| No                         | 0.86 (0.49–1.52)    |               |
| **LVI**                    |                     |               |
| Yes                        | 1                   | 0.047         |
| No                         | 0.66 (0.44–0.99)    |               |
| **Tumor size (cm)**        |                     |               |
| \( \leq 3 \)               | 1                   | 0.079         |
| \( >3, \leq 5 \)          | 1.88 (1.14–3.08)    | 0.012         |
| \( >5 \)                   | 2.31 (1.32–4.05)    | 0.003         |
| **Cycles of Chemotherapy** |                     |               |
| \( \leq 4 \)               | 1                   | 0.003         |
| \( >4 \)                   | 0.70 (0.47–1.04)    |               |
| **PORT to the lung**       |                     |               |
| Yes                        | 1                   | 0.003         |
| No                         | 1.81 (1.22–2.68)    |               |
| **PCI**                    |                     |               |
| Yes                        | 1                   | 0.004         |
| No                         | 1.89 (1.23–2.89)    |               |
| **Node levels**            |                     |               |
| Single-station N2          | 1                   | 0.003         |
| Multiple-station N2        | 1.78 (1.21–2.61)    |               |
| **Node-spreading patterns** |                    |               |
| Nonskip N2                 | 1                   | 0.103         |

Abbreviations: PET positron emission tomography, SCLC small cell lung cancer, LVI lymphovascular invasion, PORT postoperative radiotherapy, PCI prophylactic cranial irradiation, HR hazard ratio, CI confidence interval

### Table 3 Multivariate analysis for overall survival

| Variables                  | Multivariate Analysis |  \( p \) value |
|----------------------------|                       |               |
| **Age**                    |                        |               |
| < 60 years                 | 1                       | 0.411         |
| ≥ 60 years                 | 1.19 (0.78–1.81)        |               |
| **Gender**                 |                        |               |
| Male                       | 1                       | 0.420         |
| Female                     | 1.34 (0.65–2.73)        |               |
| **Smoking status**         |                        |               |
| Smoker                     | 1                       | 0.520         |
| Never-smoker               | 0.81 (0.44–1.51)        |               |
| **Tumor endoscopy**        |                        |               |
| Peripheral                 | 1                       | 0.017         |
| Central                    | 1.79 (1.11–2.90)        |               |
| **LVI**                    |                        |               |
| Yes                        | 1                       | 0.420         |
| No                         | 0.83 (0.53–1.29)        |               |
| **Tumor size (cm)**        |                        |               |
| \( \leq 3 \)               | 1                       | 0.174         |
| \( >3, \leq 5 \)          | 1.46 (0.84–2.52)        | 0.174         |
| \( >5 \)                   | 1.65 (0.74–3.64)        | 0.216         |
| **PORT to the lung**       |                        |               |
| Yes                        | 1                       | 0.041         |
| No                         | 1.53 (1.01–2.32)        |               |
| **PCI**                    |                        |               |
| Yes                        | 1                       | 0.002         |
| No                         | 2.10 (1.31–3.36)        |               |
| **Node levels**            |                        |               |
| Single-station N2          | 1                       | 0.006         |
| Multiple-station N2        | 1.84 (1.19–2.84)        |               |
| **Subcarinal LN metastasis** |                    |               |
| No                         | 1                       | 0.037         |
| Yes                        | 1.57 (1.02–2.41)        |               |

Abbreviations: SCLC small cell lung cancer, LVI lymphovascular invasion, PORT postoperative radiotherapy, PCI prophylactic cranial irradiation, HR hazard ratio, CI confidence interval
Patients with subcarinal node involvement from right or left hilar LN should be dissected or sampled routinely during operations for SCLC to avoid understaging.

We have no ready explanation for the poor prognosis of patients with subcarinal LN metastases. We speculate that the subcarinal node might be significant as a common path where the lymphatic channels from various organs in the thorax meet, either directly or by means of lymphoid relays [27]. Our own study confirmed the importance of the subcarinal LN and the poor prognostic implications. The underlying reason for these results may be that subcarinal LN metastasis indicates a wider range of mediastinal involvement and widespread micro-metastasis via the lymphatic network. Thus, SCLC with subcarinal metastases might be more advanced and have a higher biological potential for spread than SCLC without subcarinal metastases in patients with pN2 disease.

Our study had several limitations. Specifically, the study was retrospective from a single institution with a small number of patients over a long study period, and lack of cohort design, which might cause selection bias. Second, there was no central pathologic review, although histologic staging of suspicious nodes. Before surgery, patients who had a dissected LN number of < 6. Fourth, pre-operative PET scan, mediastinoscopy, and endobronchial ultrasound were not routinely performed for pathologic staging of suspicious nodes. Before surgery, patients with mediastinal lymph nodes received EBUS. If the biopsy of mediastinal lymph nodes was negative, patients were selected for an operation. In the current study, only 63 (38.7%) patients receive PET to assess the mediastinal lymph nodes, which is a source of potential weakness because some patients with a poor prognosis may be enrolled in this study. Further evaluation is needed to

Table 4: Multivariate logistic regression analysis of factors correlated to subcarinal lymph node metastasis

| Variables                   | OR   | 95%CI     | p value |
|-----------------------------|------|-----------|---------|
| Tumour location             |      |           |         |
| Upper lobe$^a$              | 1.00 |           |         |
| Middle lobe                 | 1.83 | 1.05–3.18 | 0.035   |
| Lower lobe                  | 8.32 | 3.72–18.60| < 0.05  |
| Node levels                 |      |           |         |
| Single-station N2$^a$        | 4.04 | 1.85–8.81 | < 0.05  |
| Multiple-station N2          | 4.04 | 1.85–8.81 | < 0.05  |

Abbreviations: OR odds ratio, CI confidence interval

$^a$Reference category

however, other reports with contradictory findings also exist [7, 18, 19]. In SCLC, Leuzzi et al. [20] found N0 N2-patients showed a worse cancer-specific survival compared to patients with combined N1 N2-involvement (N0 N2 [8 months] versus N1 N2 [22 months]; p = 0.04). Our data showed no statistically significant difference in survival between patients with skip and non-skip N2 metastases. Further studies with larger cohorts are needed to define the prognostic role of the node-spreading patterns.

Moreover, the locations of the LNs involved may also have prognostic significance. Okada et al. [21] suggested that the subcarinal LN is an independent prognostic factor among pN2 NSCLC patients with an upper lobe tumor (p = 0.023). Patients with subcarinal node involvement from right or left upper lobe tumors (n = 8) have a significantly worse prognosis than patients with metastases to the upper mediastinal or aortic nodes only (n = 70), and the 5-year survival for these patients was 0 and 37%, respectively. These results are in agreement with the results reported by others [22–24], confirming a poor outcome in NSCLC with subcarinal LN involvement. Few studies have investigated the prognostic value of subcarinal LN metastasis in patients with SCLC. Miyamoto et al. [25] suggested that the prognosis was significantly poorer in SCLC patients with subcarinal LN involvement than those without subcarinal LN involvement and pN2 disease (p = 0.0319) by univariate analysis, which was consistent with the previous reports involving NSCLC.

In the current study, it was surprising that subcarinal LN had a high incidence of involvement (45.4% [74 of 163]) in pN2 IIIA SCLC. Such a high incidence reflects the virtual situation that has been commonly neglected. Thus, subcarinal LN metastasis was significantly more common in patients with lower lobe or middle lobe cancers compared with upper lobe cancers (70.9% versus 21.4%, p < 0.05). In addition, we concluded that tumor location and node levels were significant variables for identifying patients with subcarinal LN metastasis. Our study showed that subcarinal LN metastasis is a predictive factor for worse OS in patients with pN2 IIIA SCLC regardless of tumor location. The median OS for patients with subcarinal LN metastasis was significantly shorter than patients without subcarinal LN metastasis (16.14 months versus 29.36 months, p < 0.05), the survival of 16.14 months was nearly the same with that reported for patients receiving chemoradiation alone in the presence of stage III/N2 disease. The National Cancer Data Base (NCDB) analysis found that compared to chemotherapy-based non-surgical treatment, surgery was associated with longer survival for SCLC patients with stage IIIA (median OS 21.7 vs. 16.0 months, p < 0.0001) and node positivity(N2+ 20.1 vs. 14.6 months p = 0.007) [26]. Because the prognosis of small cell lung cancer patients with subcarinal nodal disease is poor, accurate staging is important to direct patients to the most effective treatments, chemoradiation but not surgery may be more potent for these patients. Although subcarinal nodal biopsy is not essential to determine resectability, subcarinal LN should be dissected or sampled routinely during operations for SCLC to avoid understaging.
evaluate the impact of the LN status on survival of patients with pN2 IIIA SCLC and confirm our results.

Conclusions
Our study showed that N2 levels and subcarinal LN metastasis were significant indicators of worse OS in patients with completely resected pN2 IIIA SCLC. The differences in survival between these sub-groups of patients suggest that they should be considered for more aggressive adjuvant therapy and different postsurgical follow-up strategies. Our data demonstrated the validity of avoiding surgery after identifying the sites (subcarinal level) of potential nodal metastases of SCLC with N2. Larger prospective clinical trials evaluating the role of the adjuvant therapies should divide patients into separate groups based on these factors.

Abbreviations
CI: Confidence interval; ECOG: Eastern Cooperative Oncology Group; HR: Hazard ratios; LN: Lymph node; LVI: Lymphovascular invasion; NSCLC: Non-small cell lung cancer; OS: Overall survival; PCI: Prophylactic cranial irradiation; PET: Positron emission tomography; pN2: Pathologic N2; PORT: Postoperative radiotherapy; SCLC: Small cell lung cancer

Acknowledgements
The authors would like to thank the surgeons, nursing staff and the laboratory department at the Shanghai Chest Hospital for the collection and management of the data presented in this report.

Funding
Research reported in this publication was supported by the Shanghai Municipal commission of Health and Family Planning Support Grant (20174Y0121).

Availability of data and materials
Database collected in the study is available from the corresponding author on reasonable request.

Authors’ contributions
Dr. Han had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr. Qiao and Dr. Xu contributed substantially to the study design, writing and revisions of the manuscript and served as principal authors. Dr. Bo Zhang, Dr. Shuyuan Wang, Dr. Yuqing Lou and Dr. Yanwei Zhang contributed to the data analysis and interpretation. Dr. Qiang Chang and Dr. Dongfang Chen contributed to the data acquisition. Dr. Runbo Zhong and Dr. Yizhuo Zhao contributed to the review of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the Ethics Committee of Shanghai Chest Hospital.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
2. Gaspar LE, McNamara EJ, Gay EG, Putnam JB, Crawford J, Herbst RS, et al. Small-cell lung cancer: prognostic factors and changing treatment over 15 years. Clin Lung Cancer. 2012;13:115–22.
3. van Meerbeeck JP, Fennell DA, De Ruyscher DK. Small cell lung cancer. Lancet. 2011;378:1741–55.
4. Schreiber D, Rieker J, Weedon J, Vaghtana D, Wortham A, Kim A, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer. 2010;116:1350–7.
5. Combs SE, Hancock JG, Boffa DJ, Combs SE, Hancock JG, Boffa DJ, et al. Bolstering the case for lobectomy in stages I, II and IIIA small cell lung cancer using the national cancer data base. J Thorac Oncol. 2015;10:316–23.
6. Rusch VW, Asamura H, Watanabe H, Ghioulx DJ, Rami-Porta R, Goldstraw P, et al. The IASLC lung cancer staging project. A proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:568–77.
7. Casali C, Stefani A, Natali P, Rossi G, Morandi U. Prognostic factors in surgically resected N2 non-small cell lung cancer: the importance of patterns of mediastinal lymph nodes metastases. Eur J Cardiothorac Surg. 2005;28:33–8.
8. Andre F, Gunenwald D, Pigon JP, Dujon A, Pujol JL, Brichon PY, et al. Survival of patients with resected N2 non-small cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000;18:2981–9.
9. Ichinose Y, Kato H, Koike T, Tsuchiya R, Fujisawa T, Shimizu N, et al. Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station. J Thorac Cardiovasc Surg. 2001;122:829–38.
10. Fukui T, Mori S, Yokoi K, Mitromodi T. Significance of the number of positive lymph nodes in resected non-small cell lung cancer. J Thorac Oncol. 2006;1:120–5.
11. Kang CH, Ra YJ, Kim YT, Jheon SH, Sung SW, Kim JH. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 non-small-cell lung cancer. Ann Thorac Surg. 2008;86:1092–7.
12. Sonobe M, Date H, Wada H, Okubo K, Hamakawa H, Teramukai S, et al. The Japan-Multinational Trial Organization. Prognostic factors after complete resection of pN2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013;146:788–95.
13. Ilic N, Petricovic A, Arad D, Kotonac S, Banovic J, Ilic NF, et al. Skip mediastinal nodal metastases in the Ilia/N2 non-small cell lung cancer. J Thorac Oncol. 2007;2:1018–21.
14. Ichinose Y, Kato H, Koike T, Tsuchiya R, Fujisawa T, Shimizu N, et al. Overall survival and local recurrence of 406 completely resected stage Ilia/N2 non-small cell lung cancer patients: questionnaire survey of the Japan clinical oncology group to plan for clinical trials. Lung Cancer. 2001;34:29–36.
15. Nakagiri T, Sawabata N, Funaki S, Inoue M, Kadota Y, Shintani Y, et al. Validation of pN2 sub-classifications in patients with pathological stage IIA N2 non-small cell lung cancer. Int J Cardiovasc Thorac Surg. 2011;12:733–8.
16. Ohta Y, Shimizu Y, Minato H, Matsumoto I, Oda M, Watanabe G. Results of initial operations in non-small cell lung cancer patients with single-level N2 disease. Ann Thorac Surg. 2006;81:427–33.
17. Riquet M, Assouad J, Bagan P, Foulcalt C, Le Pimpec Barthes F, et al. Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis. Ann Thorac Surg. 2005;79:225–33.
18. Lee JG, Lee CY, Park IK, Kim DJ, Cho SH, Kim KD, et al. The prognostic significance of multiple station N2 in patients with surgically resected IIA N2 non-small cell lung cancer. J Korean Med Sci. 2008;23:604–8.
19. Mithos P, Seips E, Kokotsakis J, Skotits I, Lioulia A. The significance of oesophageal N2 disease in the prognosis of patients with non-small-cell lung cancer. Ann Thorac Surg. 2008;86:1626–31.
20. Leuzzi G, Lococo F, Alessandrini G, Spedelui I, Spaggiari L, Venuta F, et al. Prognostic impact of node-spreading pattern in surgically treated small-cell lung cancer: a multicentric analysis. Lung. 2017;195:107–14.
21. Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Matsuoka H. Prognosis of completely resected pN2 non-small cell lung carcinomas: what is the
significant node that affects survival? J Thorac Cardiovasc Surg. 1999;118:270–5.

22. Aokage K, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Subcarinal lymph node in upper lobe non-small cell lung cancer patients: is selective lymph node dissection valid? Lung Cancer. 2010;70:163–7.

23. Naruke T, Suematsu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg. 1978;76:832–9.

24. Kirsh M, Sloan H. Mediastinal metastases in bronchogenic carcinoma: influence of postoperative irradiation, cell type, and locations. Ann Thorac Surg. 1982;33:459–66.

25. Miyamoto M, Morikawa T, Kaga K, Ohtake S, Cho Y, Hirano S, et al. Subcarinal node is the significant node that affects survival in resected small cell lung cancer. Surg Today. 2006;36:671–5.

26. Wakeham E, Acuna SA, Leighl NB, et al. Surgery versus chemotherapy and radiotherapy for early and locally advanced small cell lung cancer: a propensity-matched analysis of survival. Lung Cancer. 2017;109:78–88.

27. Okada M, Tsubota N, Yoshimura M, Miyamoto Y. Proposal for reasonable mediastinal lymphadenectomy in bronchogenic carcinomas: role of subcarinal node in selective dissection. J Thorac Cardiovasc Surg. 1998;116:949–53.